+1 732.247.2390

Contact

EN

/ 中文

LOGIN

Search

High Fat, Fructose, and Cholesterol Diets for NAFLD

by | May 15, 2026 | Formulation Insights, Product Literature (Diet) | 0 comments

Abstract  

Nonalcoholic fatty liver disease (NAFLD) is intricately linked to metabolic disease (including obesity, glucose intolerance, and insulin resistance) and encompasses a spectrum of disorders including steatosis, nonalcoholic steatohepatitis (NASH), and fibrosis. Rodents consuming high-fat (HF;∼40 kcal% fat including fats containing higher concentrations of saturated and trans fats), high-fructose (HFr), and high-cholesterol (HC) diets display many clinically relevant characteristics of NASH, along with other metabolic disorders. C57BL/6 mice are the most commonly used animal model because they can develop significant metabolic disorders including severe NASH with fibrosis after months of feeding, but other models also are susceptible. The significant number of diets that contain these different factors (i.e., HF, HFr, and HC), either alone or in combination, makes the choice of diet difficult. This methodology review describes the efficacy of these nutrient manipulations on the NAFLD phenotype in mice, rats, guinea pigs, hamsters, and nonhuman primates. Curr Dev Nutr 2021;5:nzab138.

Download the PDF

References

  1. Kristiansen MN, Veidal SS, Rigbolt KT, Tolbol KS, Roth JD, Jelsing J, Vrang N, Feigh M. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol 2016;8(16):673–84.
  2. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008;23(11):1635–48.
  3. Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: definitions, risk factors, andworkup.ClinLiverDis(Hoboken)2012;1(4):99–103.
  4. EstesC,RazaviH,LoombaR,YounossiZ,SanyalAJ.Modelingtheepidemicof nonalcoholic fatty liver disease demonstrates an exponential increase in burdenofdisease.Hepatology2018;67(1):123–33.
  5. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R. The economic and clinical burden of nonalcoholicfattyliverdiseaseintheUnitedStatesandEurope.Hepatology2016;64(5):1577–86.
  6. Radhakrishnan S, Ke JY, Pellizzon MA. Targeted nutrient modifications in purified diets differentially affect nonalcoholic fatty liver disease and metabolic disease development in rodent models. Curr Dev Nutr 2020;4(6):nzaa078.
  7. Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. DrugDiscovToday2017;22(11):1707–18.
  8. RicciMR,UlmanEA.Laboratoryanimaldiets:acriticalpartofyourinvivo research.AnimLabNews2005;4(6):26–31.
  9. Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, Celeste A, Trevaskis JL. Superior reductions in hepatic steatosis and fibrosis with co-administrationofaglucagon-likepeptide-1receptoragonistandobeticholic acidinmice.MolMetab2017;6(11):1360–70.
  10. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Animal models of fibrosis in nonalcoholic steatohepatitis: do they reflect human disease? Adv Nutr 2020;11(6):1696–711.
  11. KatsikiN,Perez-MartinezP,AnagnostisP,MikhailidisDP,KaragiannisA.Is nonalcoholicfattyliverdiseaseindeedthehepaticmanifestationofmetabolic syndrome?CurrVascPharmacol2018;16(3):219–27.
  12. Gastaldelli A. Fatty liver disease: the hepatic manifestation of metabolic syndrome.HypertensRes2010;33(6):546–7.
  13. Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: a consensus-drivenproposednomenclatureformetabolicassociatedfattyliver disease.Gastroenterology2018;158(7):1999–2014.e1.
  14. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest LiverPhysiol2008;295(5):G987–95.
  15. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J PhysiolGastrointestLiverPhysiol2012;302(8):G762–72.
  16. US FDA. Final determination regarding partially hydrogenated oils (removingtransfat)[Internet].SilverSpring,MD:USFDA;2018.Available from: https://www.fda.gov/food/food-additives-petitions/final-determina tion-regarding-partially-hydrogenated-oils-removing-trans-fat, [accessed 18May,2018].
  17. Boland M, Oró D, Tølbøl KS, Thrane S, Nielsen JC, Cohen T, Tabor D, Fernandes F, Tovchigrechko A, Veidal SS, et al. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: impact of dietary fat source. World J Gastroenterol 2019;25(33):4904–20.
  18. DrescherHK,WeiskirchenR,FülöpA,HopfC,deSanRománEG,Huesgen PF, de Bruin A, Bongiovanni L, Christ A, Tolba R, et al. The influence of different fat sources on steatohepatitis and fibrosis development in the Western diet mouse model of non-alcoholic steatohepatitis (NASH). Front Physiol2019;10:770.
  19. Dowman JK, Hopkins LJ, Reynolds GM, Nikolaou N, Armstrong MJ, Shaw JC, Houlihan DD, Lalor PF, Tomlinson JW, Hubscher SG, et al. Developmentofhepatocellularcarcinomainamurinemodelofnonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.AmJPathol2014;184(5):1550–61.
  20. MatsuzawaN,TakamuraT,KuritaS,MisuH,OtaT,AndoH,YokoyamaM, Honda M, Zen Y, Nakanuma Y, et al. Lipid-induced oxidative stress causes steatohepatitisinmicefedanatherogenicdiet.Hepatology2007;46(5):1392–403.
  21. Subramanian S, Goodspeed L, Wang S, Kim J, Zeng L, Ioannou GN, Haigh WG, Yeh MM, Kowdley KV, O’Brien KD, et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficientmice.JLipidRes2011;52(9):1626–35.
  22. Zheng S, Hoos L, Cook J, Tetzloff G, Davis H Jr, van Heek M, Hwa JJ. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008;584(1):118–24.
  23. Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, Narimatsu K, Okada Y, Kurihara C, Irie R, Yokoyama H, et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014;59(1):154–69.
  24. Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, Chait A, Yeh MM, Quinn LS, Ioannou GN. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013;57(1):81–92.
  25. Clapper JR, Hendricks MD, Gu G, Wittmer C, Dolman CS, Herich J, Athanacio J, Villescaz C, Ghosh SS, Heilig JS, et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol 2013;305(7):G483–95.
  26. Lee SM, Pusec CM, Norris GH, De Jesus A, Diaz-Ruiz A, Muratalla J, Sarmento-Cabral A, Guzman G, Layden BT, Cordoba-Chacon J. Hepatocyte-specific loss of PPARγ protects mice from NASH, and increases the therapeutic effects of rosiglitazone in the liver. Cell Mol Gastroenterol Hepatol 2021;11(5):1291–311.
  27. Kawashita E, Ishihara K, Nomoto M, Taniguchi M, Akiba S. A comparative analysis of hepatic pathological phenotypes in C57BL/6J and C57BL/6N mouse strains in non-alcoholic steatohepatitis models. Sci Rep 2019;9(1):204.
  28. Chiappini F, Coilly A, Kadar H, Gual P, Tran A, Desterke C, Samuel D, Duclos-Vallee JC, Touboul D, Bertrand-Michel J, et al. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients. Sci Rep 2017;7(1):46658.
  29. Liangpunsakul S, Chalasani N. Lipid mediators of liver injury in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2019;316(1):G75–81.
  30. Rom O, Xu G, Guo Y, Zhu Y, Wang H, Zhang J, Fan Y, Liang W, Lu H, Liu Y, et al. Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice. EBioMedicine 2019;41:62–72.
  31. Zhang H, Léveillé M, Courty E, Gunes A, Nguyen BN, Estall JL. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 2020;319(5):E863–76.
  32. Asimakopoulou A, Engel KM, Gassler N, Bracht T, Sitek B, Buhl EM, Kalampoka S, Pinoe-Schmidt M, van Helden J, Schiller J, et al. Deletion of perilipin 5 protects against hepatic injury in nonalcoholic fatty liver disease via missing inflammasome activation. Cells 2020;9(6):1346.
  33. Chyau C-C, Wang H-F, Zhang W-J, Chen C-C, Huang S-H, Chang C-C, Peng RY. Antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in C57BL/6 mice model via AMPK/Sirt1/SREBP-1c/PPARγ pathway. Int J Mol Sci 2020;21(1):360.
  34. Antunes MM, Diniz AB, Castro-Oliveira HM, Mendes GAM, Freitas-Lopes MA, de Oliveira Costa KM, Bicalho KM, Nakagaki BNL, Mattos MS, de Miranda CDM, et al. Chronic ingestion of Primex-Z, compared with other common fat sources, drives worse liver injury and enhanced susceptibility to bacterial infections. Nutrition 2021;81:110938.
  35. Suzuki-Kemuriyama N, Abe A, Uno K, Ogawa S, Watanabe A, Sano R, Yuki M, Miyajima K, Nakae D. A trans fatty acid substitute enhanced development of liver proliferative lesions induced in mice by feeding a choline-deficient, methionine-lowered, L-amino acid-defined, high-fat diet. Lipids Health Dis 2020;19(1):251.
  36. Hansen HH, Ægidius HM, Oró D, Evers SS, Heebøll S, Eriksen PL, Thomsen KL, Bengtsson A, Veidal SS, Feigh M, et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020;20(1):210.
  37. Ægidius HM, Veidal SS, Feigh M, Hallenborg P, Puglia M, Pers TH, Vrang N, Jelsing J, Kornum BR, Blagoev B, et al. Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis. Sci Rep 2020;10(1):1148.
  38. Kannt A, Wohlfart P, Madsen AN, Veidal SS, Feigh M, Schmoll D. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br J Pharmacol 2021;178(12):2412–23.
  39. Lee SM, Muratalla J, Diaz-Ruiz A, Remon-Ruiz P, McCann M, Liew CW, Kineman RD, Cordoba-Chacon J. Rosiglitazone requires hepatocyte PPARγ expression to promote steatosis in male mice with diet-induced obesity. Endocrinology 2021;162(11):bqab175.
  40. Kannt A, Madsen AN, Kammermeier C, Elvert R, Klockener T, Bossart M, Haack T, Evers A, Lorenz K, Hennerici W, et al. Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. Diabetes Obes Metab 2020;22(8):1328–40.
  41. Sun G, Jackson CV, Zimmerman K, Zhang L-K, Finnearty CM, Sandusky GE, Zhang G, Peterson RG, Wang Y-XJ. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose. BMC Gastroenterol 2019;19(1):41.
  42. Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, Kumar DP, Daita K, Min H-K, Mirshahi F, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol 2016;65(3):579–88.
  43. Wang X, Zheng Z, Caviglia JM, Corey KE, Herfel TM, Cai B, Masia R, Chung RT, Lefkowitch JH, Schwabe RF, et al. Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab 2016;24(6):848–62.
  44. Gluchowski NL, Gabriel KR, Chitraju C, Bronson RT, Mejhert N, Boland S, Wang K, Lai ZW, Farese RV Jr, Walther TC. Hepatocyte deletion of triglyceride-synthesis enzyme acyl CoA: diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice. Hepatology 2019;70(6):1972–85.
  45. Kawasaki T, Igarashi K, Koeda T, Sugimoto K, Nakagawa K, Hayashi S, Yamaji R, Inui H, Fukusato T, Yamanouchi T. Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J Nutr 2009;139(11):2067–71.
  46. Lee JS, Jun DW, Kim EK, Jeon HJ, Nam HH, Saeed WK. Histologic and metabolic derangement in high-fat, high-fructose, and combination diet animal models. Sci World J 2015;2015:306326.
  47. Ichimura M, Kawase M, Masuzumi M, Sakaki M, Nagata Y, Tanaka K, Suruga K, Tamaru S, Kato S, Tsuneyama K, et al. High-fat and high-cholesterol diet rapidly induces non-alcoholic steatohepatitis with advanced fibrosis in Sprague-Dawley rats. Hepatol Res 2015;45(4):458–69.
  48. Kitamori K, Naito H, Tamada H, Kobayashi M, Miyazawa D, Yasui Y, Sonoda K, Tsuchikura S, Yasui N, Ikeda K, et al. Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. Environ Health Prev Med 2012;17(3):173–81.
  49. Ikemoto S, Takahashi M, Tsunoda N, Maruyama K, Itakura H, Kawanaka K, Tabata I, Higuchi M, Tange T, Yamamoto TT, et al. Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease. Am J Physiol 1997;273(1 Pt 1):E37–45.
  50. Torres-Villalobos G, Hamdan-Pérez N, Tovar AR, Ordaz-Nava G, Martínez-Benítez B, Torre-Villalvazo I, Morán-Ramos S, Díaz-Villaseñor A, Noriega LG, Hiriart M, et al. Combined high-fat diet and sustained high sucrose consumption promotes NAFLD in a murine model. Ann Hepatol 2015;14(4):540–6.
  51. Jensen VS, Hvid H, Damgaard J, Nygaard H, Ingvorsen C, Wulff EM, Lykkesfeldt J, Fledelius C. Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats. Diabetol Metab Syndr 2018;10:4.
  52. Hinojosa G, Hamilton A, Lora J, Short JD, Dearth RK. Characterizing a rat model to study the role endo-immunology plays in diet-induced non-alcoholic fatty liver disease. FASEB J 2017;31(S1):887.17.
  53. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med 2001;11(5):170–6.
  54. Zhang Z, Cianflone K, Sniderman AD. Role of cholesterol ester mass in regulation of secretion of apoB100 lipoprotein particles by hamster hepatocytes. Arterioscler Thromb Vasc Biol 1999;19(3):743–52.
  55. Basciano H, Miller AE, Naples M, Baker C, Kohen R, Xu E, Su Q, Allister EM, Wheeler MB, Adeli K. Metabolic effects of dietary cholesterol in insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab 2009;297(2):E462–73.
  56. Briand F, Brousseau E, Quinsat M, Burcelin R, Sulpice T. Obeticholic acid in diet-induced NASH hamster model. Eur J Pharmacol 2018;818:449–56.
  57. Jensen VS, Fledelius C, Wulff EM, Lykkesfeldt J, Hvid H. Temporal development of dyslipidemia and NAFLD in Syrian hamsters. Nutrients 2021;13(2):604.
  58. Lai Y-S, Yang T-C, Chang P-Y, Chang S-F, Ho S-L, Chen H-L, Lu S-C. Electronegative LDL linked to NASH in hamsters. J Nutr Biochem 2016;30:44–52.
  59. Fernandez ML, Volek JS. Guinea pigs as model for lipid metabolism and inflammation. Nutr Metab 2006;3:17.
  60. Tveden-Nyborg P, Birck MM, Ipsen DH, Thiessen T, Feldmann LdB, Lindblad MM, Jensen HE, Lykkesfeldt J. Dyslipidemia leads to NAFLD in guinea pigs. Transl Res 2016;168:146–60.
  61. Ipsen DH, Tveden-Nyborg P, Rolin B, Rakipovski G, Beck M, Mortensen LW, Faerk L, Heegaard PM, Møller P, Lykkesfeldt J. High-fat but not sucrose intake is essential for NASH in guinea pigs. Nutr Metab 2016;13:51.
  62. Jensen VS, Tveden-Nyborg P, Zacho-Rasmussen C, Quaade ML, Ipsen DH, Hvid H, Fledelius C, Wulff EM, Lykkesfeldt J. Variation in NAFLD read-outs in rodent models. J Pharmacol Toxicol Methods 2020;101:106651.
  63. Ipsen DH, Agerskov RH, Klaebel JH, Lykkesfeldt J, Tveden-Nyborg P. Breeder-dependent variation in NASH guinea pigs. Sci Rep 2021;11:2955.
  64. Bremer AA, Stanhope KL, Graham JL, Cummings BP, Wang W, Saville BR, Havel PJ. Fructose-fed rhesus monkeys as model of insulin resistance. Clin Transl Sci 2011;4(4):243–50.
  65. Cydylo MA, Davis AT, Kavanagh K. Fatty liver promotes fibrosis in monkeys consuming high fructose. Obesity 2017;25(2):290–3.
  66. Kavanagh K, Wylie AT, Tucker KL, Hamp TJ, Gharaibeh RZ, Fodor AA, Cullen JM. Dietary fructose induces endotoxemia in primates. Am J Clin Nutr 2013;98(2):349–56.
  67. Camacho R, Polidori D, Chen T, Gao B, Wong P, Gabriel J, Zhu E, Wang T, Nawrocki A. Pioglitazone improves NASH in cynomolgus monkeys. Diabetes 2020;69(Suppl 1):1827-P.
  68. Schumacher-Petersen C, Christoffersen BO, Kirk RK, Ludvigsen TP, Zois NE, Pedersen HD, Vyberg M, Olsen LH. Experimental NASH in Göttingen minipigs. J Transl Med 2019;17:110.
  69. Pellizzon MA, Ricci MR. Improper control diets confound metabolic disease research. Nutr Metab 2018;15:3.
  70. Pellizzon MA, Ricci MR. Effects of rodent diet choice and fiber type on metabolic research interpretation. Curr Protoc Toxicol 2018;77:e55.

Submit a Comment

Your email address will not be published. Required fields are marked *